|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Pathophysiology/Complications |
Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol
The Veterans Affairs HDL Intervention Trial (VA-HIT)
1 Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
2 Center for Chronic Disease Outcomes Research, VAMC, Minneapolis, Minnesota
3 Department of Medicine, VAMC, Little Rock, Arkansas
4 Lipid Research Laboratory, Tufts University School of Medicine, Boston, Massachusetts
5 Department of Medicine, VAMC, Memphis, Tennessee
6 Department of Medicine, VAMC, Lexington, Kentucky
7 Department of Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Connecticut
OBJECTIVE—To assess the effect of insulin resistance and the benefit of the fibrate, gemfibrozil, on the incidence of major cardiovascular events in subjects with low HDL cholesterol and a broad range of triglyceride values who participated in the Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT).
RESEARCH DESIGN AND METHODS—This intention-to-treat analysis, specified as a secondary objective in VA-HIT, determined using Cox proportional hazards models the 5-year combined incidence of nonfatal myocardial infarction, coronary heart disease (CHD) death, or stroke in relation to the presence or absence of insulin resistance (defined by the highest tertile of the homeostasis model assessment of insulin resistance, HOMA-IR) in conjunction with lower and higher levels of HDL cholesterol and triglycerides. The study population consisted of 2,283 men with known coronary heart disease (CHD), treated with either placebo or gemfibrozil, who could be subdivided into groups with diabetes with or without insulin resistance, with no diabetes but insulin resistance, and with neither diabetes nor insulin resistance.
RESULTS—With insulin resistance there was a significantly higher relative risk (RR) of a cardiovascular event both with diabetes (RR of 1.62 with 95% CI of 1.28–2.06) and without diabetes (RR of 1.43 with 95% CI of 1.03–1.98) than without insulin resistance. Throughout both lower and higher ranges of HDL cholesterol and triglycerides, the rate of new cardiovascular events and the reduction of events with gemfibrozil was greater in subjects with insulin resistance than without, despite the finding that an increase in HDL cholesterol and a decrease in triglycerides with gemfibrozil was less with insulin resistance than without insulin resistance.
CONCLUSIONS—Results show that in VA-HIT the occurrence of a new cardiovascular event and the benefit of fibrate therapy was much less dependent on levels of HDL cholesterol or triglycerides than on the presence or absence of insulin resistance.
Abbreviations: CHD, coronary heart disease • HOMA-IR, homeostasis model assessment of insulin resistance • MI, myocardial infarction • VA-HIT, Veterans Affairs High Density Lipoprotein Intervention Trial
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. K. Rutter, P. W.F. Wilson, L. M. Sullivan, C. S. Fox, R. B. D'Agostino Sr, and J. B. Meigs Use of Alternative Thresholds Defining Insulin Resistance to Predict Incident Type 2 Diabetes Mellitus and Cardiovascular Disease Circulation, February 26, 2008; 117(8): 1003 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Goldenberg, M. Benderly, U. Goldbourt, and for the BIP Study Group Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 459 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Insulin Resistance, Dyslipidemia, and Cardiovascular Disease Diabetes Care, August 1, 2007; 30(8): 2164 - 2170. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sheikh, G. Camejo, B. Lanne, T. Halvarsson, M. R. Landergren, and N. D. Oakes Beyond lipids, pharmacological PPAR{alpha} activation has important effects on amino acid metabolism as studied in the rat Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1157 - E1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J. B. Meigs, R. C. Bonadonna, and M. Muggeo Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population: The Bruneck Study Diabetes Care, February 1, 2007; 30(2): 318 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. M. Zadelaar, L. S.M. Boesten, J. W. Jukema, B. J.M. van Vlijmen, T. Kooistra, J. J. Emeis, E. Lundholm, G. Camejo, and L. M. Havekes Dual PPAR{alpha}/{gamma} Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2560 - 2566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. Bloomfield The role of fibrates in a statin world. Arch Intern Med, April 10, 2006; 166(7): 715 - 716. [Full Text] [PDF]
|
|
|
|
|
|
L. Tenkanen, M. Manttari, P. T. Kovanen, H. Virkkunen, and V. Manninen Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study. Arch Intern Med, April 10, 2006; 166(7): 743 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Otvos, D. Collins, D. S. Freedman, I. Shalaurova, E. J. Schaefer, J. R. McNamara, H. E. Bloomfield, and S. J. Robins Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation, March 28, 2006; 113(12): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]
|
|
|
|
|
|
B. Fletcher, K. Berra, P. Ades, L. T. Braun, L. E. Burke, J. L. Durstine, J. M. Fair, G. F. Fletcher, D. Goff, L. L. Hayman, et al. Managing Abnormal Blood Lipids: A Collaborative Approach Circulation, November 15, 2005; 112(20): 3184 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Rutter, J. B. Meigs, L. M. Sullivan, R. B. D'Agostino Sr, and P. W. Wilson Insulin Resistance, the Metabolic Syndrome, and Incident Cardiovascular Events in the Framingham Offspring Study Diabetes, November 1, 2005; 54(11): 3252 - 3257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Staels and J.-C. Fruchart Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists Diabetes, August 1, 2005; 54(8): 2460 - 2470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sattar and N. G. Forouhi Metabolic syndrome criteria: ready for clinical prime time or work in progress? Eur. Heart J., July 1, 2005; 26(13): 1249 - 1251. [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Reaven The Metabolic Syndrome: Requiescat in Pace Clin. Chem., June 1, 2005; 51(6): 931 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Li and C. K. Glass PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis J. Lipid Res., December 1, 2004; 45(12): 2161 - 2173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, C. N. Bairey Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, and Coordinating Committee of the National Cholesterol Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J. Am. Coll. Cardiol., August 4, 2004; 44(3): 720 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, C. N. B. Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, for the Coordinating Committee of the National Cho, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): e149 - e161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, C. N. B. Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, for the Coordinating Committee of the National Cho, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation, July 13, 2004; 110(2): 227 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Krauss Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F Watts Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses? Eur. Heart J., May 1, 2004; 25(9): 716 - 719. [Full Text] [PDF]
|
|
|
|
|
|
J. P.H. van Wijk and T. J. Rabelink PPAR-{gamma} Agonists: Shifting Attention from the Belly to the Heart? Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 798 - 800. [Full Text]
|
|
|
|
|
|
M. Ricote, A. F. Valledor, and C. K. Glass Decoding Transcriptional Programs Regulated by PPARs and LXRs in the Macrophage: Effects on Lipid Homeostasis, Inflammation, and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 230 - 239. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |